Vinci Pharmaceuticals Builds Retinal Drug Delivery Outside the Eye

Vinci Pharmaceuticals is developing EPIPLANT, a bioerodible retinal drug-delivery platform designed to sit on the outside surface of the eye and release small-molecule medication toward retinal tissue over time.

Founded in 2019, Vinci Pharmaceuticals is led by co-founders Philip A. Gioia, the company's chairman and CEO, and retinal researcher Karl Csaky, MD, PhD. The Avon-by-the-Sea, New Jersey company is preparing its lead product, EPIPLANT VCI-002, for GMP manufacturing and a planned Phase 1/2a first-in-human study in 2027.

Vinci matters because retinal medicine carries a delivery problem alongside the biology. Many therapies require repeat injections into the eye. That schedule can create a burden for patients, caregivers, and clinical teams before anyone begins debating molecules, endpoints, or market size.

EPIPLANT moves the delivery site

EPIPLANT is an episcleral implant, meaning it is placed on the outer surface of the eye rather than injected into the vitreous cavity. Vinci says the bioerodible platform is designed to provide sustained delivery to retinal tissues and can accommodate different small-molecule active ingredients.

That architecture creates a clear development thesis. If EPIPLANT can deliver a useful amount of drug for a useful duration without creating a worse procedural or safety tradeoff, Vinci may be able to build several retinal programs from one delivery platform. The company identifies diabetic macular edema and intermediate age-related macular degeneration among its target markets.

The conditional language matters. Vinci has reported preliminary preclinical testing, but it has not announced human safety, efficacy, or durability results. A delivery mechanism can look elegant on a diagram and still meet its hardest questions in manufacturing, surgery, tolerability, exposure, and follow-up.

The platform began in a retinal research laboratory

EPIPLANT was developed in the laboratory of co-founder Karl Csaky, MD, PhD and licensed from the Retina Foundation. The Retina Foundation identifies Csaky as chief medical officer and director of its molecular ophthalmology laboratory and clinical center for macular degeneration.

The public intellectual-property record gives the platform a second anchor. Patent application US20240374372A1 is assigned to Vinci Pharmaceuticals and names Csaky and Philip Gioia as inventors. The application describes ocular drug-delivery devices and methods consistent with the company's episcleral approach.

A patent is not a clinical result. It establishes a documented invention and ownership trail. For an early biotechnology company, that distinction is useful because the corporate story, scientific origin, and public record point to the same platform without asking the patent office to act like a medical journal.

The founders cover science and commercialization

Philip A. Gioia is Vinci's co-founder, chairman, and CEO. Gioia's role centers the commercial and company-building side of the business. Csaky brings retinal research, clinical-development context, and the laboratory work behind EPIPLANT.

That pairing fits the job. Ophthalmic biotechnology is not won by science or financing alone. A product has to be designed for a real clinical workflow, manufactured consistently, advanced through regulatory review, tested in people, and eventually adopted by physicians who already have treatment options and established routines.

Vinci's public team footprint remains small, and the company does not publish a careers page or a current opening count. The useful operating signal is therefore the work itself. Moving VCI-002 toward a first-in-human study requires manufacturing controls, release specifications, clinical operations, regulatory preparation, and investigators who can test the product under a defined protocol.

Capital is paying for the evidence handoff

Vinci closed more than $8 million in Series A financing in October 2026. Dynagrow Capital, LLLP led the round, with support from MintPharma Capital. Vinci previously raised $8.5 million in Seed financing, excluding interest on convertible notes, and reports more than $16.5 million in cumulative capital.

The exact Series A amount above $8 million and the company's valuation were not disclosed. What was disclosed is more useful for understanding the next stage: the proceeds are expected to fund GMP manufacturing, testing and release activities for EPIPLANT VCI-002, plus preparation for a planned Phase 1/2a study in 2027.

This is the unglamorous bridge between a platform story and a patient record. Materials have to meet specifications. Production has to be repeatable. The implant, drug, dose, release profile, procedure, and study design have to fit together well enough that human data can answer a clean question.

The retinal market rewards durability but demands proof

Retinal medicine has a strong reason to pursue longer-duration delivery. Repeat intravitreal injections can place scheduling, travel, monitoring, and procedural burdens on patients and clinics. A sustained episcleral approach could change that cadence if it delivers the right exposure with an acceptable safety profile.

Vinci is not the only company trying to improve how retinal disease is treated, and the market will not grade EPIPLANT on novelty alone. The decisive comparisons will involve safety, duration, therapeutic effect, procedural complexity, physician workflow, and the performance of existing or emerging alternatives.

The company's next milestone is therefore not another funding total. It is a credible clinical transition: reproducible product, a registered and authorized study, enrolled patients, and data that show how EPIPLANT behaves in a human eye.

What to watch next

Vinci Pharmaceuticals has a coherent platform thesis, founders whose roles match the problem, a documented intellectual-property trail, and new capital aimed at the work that precedes human testing. It also has the uncertainty every preclinical biotechnology company carries into the clinic.

Watch for completion of GMP production, a public trial registration, details on the first indication and active ingredient, investigator sites, first-patient dosing, and early safety and tolerability findings. Those records will show whether EPIPLANT is becoming a repeatable development platform or remains a promising delivery concept.

The financing buys Vinci time and operating capacity. The 2027 study is supposed to buy something more valuable: evidence that the outside of the eye can become a practical route to treating disease inside it.